AZN

U.K.-based drugmaker AstraZeneca’s (NASDAQ:AZN) metastatic non-small cell lung cancer treatment, which is a combination of Imjudo and Imfinzi along with platinum-based chemotherapy, has been approved by the U.S. Food and Drug Administration (FDA). Positive results of the POSEIDON phase 3 trial supported the regulator’s approval. Under this trial, the patients received treatment until the disease progressed or reached an unacceptable toxicity level. Further, in comparison to patients treated with a range of chemotherapy options, patients given the above-mentioned combined treatment showed a 23% lower death risk. Also, the approved treatment witnessed an estimated 33% survival rate at two years against 22% in patients with just chemotherapy.
https://www.tipranks.com/news/fda-approves-astrazenecas-nasdaqazn-lung-cancer-combination-treatment?utm_source=advfn.com&utm_medium=referral